Today (May 15th) afternoon, the Shanghai and Shenzhen stock exchanges continued their early gains. The GEM index took the lead in expanding the lead, and the Shanghai index was also on the ups and downs. In the afternoon, the industry and the concept sector went hand in hand, and the market trend was very eye-catching.
From the perspective of the disk, the industrial cannabis sector pulled up strongly in the afternoon and closed at the close.Shun Yu shares,Renhe Pharmaceutical,Guangzhou LangqiWait for stocks to go up,Morning light creature,Tonghua Golden Horse,NopsonWaiting for stocks to rise,Longjin Pharmaceutical,Fuan Pharmaceutical,Octal TechnologyWait for stocks to rise.
On the news front, according to the China Securities News, at 4 am on May 15th, Beijing time, US stock industrial cannabis leader and Canadian cannabis producer Tilray released the first quarter financial report for 2019. The financial report showed that Tilray's sales increased significantly in the first quarter, revenue nearly doubled, exceeding the average expectations of Wall Street analysts; but due to the decline in sales prices, the loss was higher than analysts expected.
A few days ago, a number of A-share companies continued to lay out industrial cannabis.Tonghua Golden HorseOn the evening of May 14, the company announced that the company signed the "Industrial Cannabis Cooperation Project Agreement" with the Qitaihe Municipal People's Government of Heilongjiang Province and the Heilongjiang Academy of Sciences to expand the company's deep development in the field of industrial cannabis breeding, planting, extraction and deep processing. , the implementation of industrial cannabis scientific and technological research and development and transformation.
In addition, on the evening of May 13,Australian Ocean HealthThe announcement said that the holding subsidiary Suining Aoyang Technology Co., Ltd. and Heilongjiang Zhaoguang Farm signed the "Strategic Cooperation Agreement" in Zhangjiagang on the same day. According to the agreement, Zhaoguang Farm is responsible for planting industrial cannabis with an annual output of no more than 500 mu. The seed variety is Qingma No. 1. The price of industrial hemp hemp sold by Zhaoguang Farm to Suining Aoyang is not higher than 7,000 yuan/mu.
Northeast SecuritiesIt is believed that unlike cannabis, industrial cannabis is not psychoactive. Industrial cannabis refers to cannabis that does not contain tetrahydrocannabinol or is less than 0.3% and can be used as food crops, cash crops and industrial raw materials. It is not psychoactive. The driving force of the industrial cannabis industry is divided into three points: First, a wide range of application scenarios; Second, the policy of the international scope continues to be liberalized; Third, the change of the traditional product is weak.
The Pacific OceanSecurities pointed out that China is the country with the largest industrial cannabis cultivation area, accounting for about half of the world's total. The output accounts for 25% of the global industrial cannabis production. In 2016, China's cannabis production was 77,000 tons. It is expected that China's cannabis production will be 2021. Up to 103,000 tons. China has strict regulations on industrial cannabis, and there are scarce resources for planting and processing licenses. At present, there are more than 30 enterprises with industrial cannabis planting licenses in China, and only 4 companies that have obtained licenses for mosaic processing (Hansu Biology, Hankang Biology, Han Musen, Baiou Bio)). Yunnan (2010) and Heilongjiang (2017) have obtained planting permits, and Jilin will become the third open industrial cannabis planting province in China. China's CBD is in the early stage of development. The only energy-production CBD is Han Su, and the downstream application market has not yet opened. Recently, domestic enterprises have laid out industrial cannabis, catalyzing the imagination of the downstream market. By the end of 2017, the market size of China's cannabisdiol industry has reached 448 million yuan, and the market size is expected to increase to 1.8 billion yuan in 2024.
Tianfeng SecuritiesIt shows that Chinese medicine companies have potential advantages in the layout, processing and application of industrial cannabis. The accumulation of medicinal planting bases has enabled the company to have the basic technology and equipment for growing industrial cannabis. Techniques such as extraction during the processing of medicinal materials are similar to industrial cannabis extraction. Chinese medicine companies have relevant technologies and channels in the research and development and promotion of pharmaceutical products.
(The content of the article is for reference only. For the stocks mentioned in the article, it does not constitute investment advice. Investors operate according to this, at their own risk.)
(Article Source:Oriental wealthSecurities Research Institute)